The latest developments in targeted therapy for triple-negative breast cancer

刘子梅; 沈　赞

doi:10.19401/j.cnki.1007-3639.2017.01.007

您当前的位置：

首页 >

文章列表页 >

The latest developments in targeted therapy for triple-negative breast cancer

更新时间：2025-12-31

- The latest developments in targeted therapy for triple-negative breast cancer
- China Oncology Vol. 27, Issue 1, Pages: 36-40(2017)
- 作者机构：
  
  上海交通大学附属第六人民医院肿瘤内科,上海,200233
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.01.007
  CLC：
- Published Online：23 February 2017，
  
  Published：23 February 2017
- 稿件说明：
移动端阅览
刘子梅,沈　赞. 三阴性乳腺癌靶向治疗最新进展[J]. 中国癌症杂志, 2017, 27(1): 36-40.

刘子梅, 沈　赞. The latest developments in targeted therapy for triple-negative breast cancer[J]. China Oncology, 2017, 27(1): 36-40.
刘子梅,沈　赞. 三阴性乳腺癌靶向治疗最新进展[J]. 中国癌症杂志, 2017, 27(1): 36-40. DOI： 10.19401/j.cnki.1007-3639.2017.01.007.

刘子梅, 沈　赞. The latest developments in targeted therapy for triple-negative breast cancer[J]. China Oncology, 2017, 27(1): 36-40. DOI： 10.19401/j.cnki.1007-3639.2017.01.007.

摘要

三阴性乳腺癌(triple-negative breast cancer，TNBC)是一种特殊类型的乳腺癌，占乳腺癌总确诊的15%~20%。其雌激素受体(estrogen receptor，ER)、孕激素受体(progesterone receptor，PR)和人表皮生长因子受体(human epidermal growth factor receptor-2，HER-2)表达均阴性，具有独特的生物学特性和临床病理特征，肿瘤异质性很高，临床上具有复发高、转移早和预后差等特点。目前，临床上缺少有效的治疗手段。该综述介绍了TNBC的临床病理特征、分子亚型、几条重要的通路和靶点，以及目前各靶向药物临床试验研究进度，希望为今后TNBC的治疗提供新的临床思路。

Abstract

Triple-negative breast cancer (TNBC) is a special type of breast cancer

accounting for 15%-20% of all diagnosed breast cancer cases. Its estrogen receptor (ER)

progesterone receptor (PR)

human epidermal growth factor receptor-2 (HER-2) expression is negative

with unique biological characteristics

clinicopathological features and tumor heterogeneity. Its clinical features include high incidence of relapse

early metastasis and poor prognosis. Currently

it lacks effective treatment. This review described the clinicopathological features of TNBC

its molecular subtypes

several important pathways and targets

as well as presented the progress in clinical studies of targeted drugs in the hope of generating new ideas for the treatment of TNBC in the future.

关键词

Keywords

references

Views

3653

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition)

TIPE regulates glucometabolic reprogramming by modulating LDHA expression in triple-negative breast cancer

Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer

The progress of treatment for brain metastases of triple-negative breast cancer

Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly

Related Author

Hongxia WANG

Yongmei YIN

Xichun HU

Wei HU

Xiaomeng REN

Yang WANG

Peiqing ZHAO

Kai CAO

Related Institution

Committee of Breast Cancer Society, Chinese Anti-Cancer Association; Clinical Precision Medicine Professional Committee, Chinese Medical Doctor Association; Tumor Heterogeneity and Personalized Therapy Professional Committee, Chinese Anti-Cancer Association

Department of Central Laboratory, Zibo Central Blood Station

Department of Breast Surgery, Zibo Central Hospital

Department of Clinical Laboratory, Huantai County People’s Hospital

Translational Medical Center, Zibo Central Hospital

AI问答

⁰